Menu
← Oncology Approval Tracker
FDA DECISION ·
Darzalex Faspro + VRd
daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide and dexamethasone · Janssen Research & Development
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Induction and consolidation with the subcutaneous daratumumab combination for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.
LAMPGEN ANALYSIS
Why it matters
The label added an anti-CD38 quadruplet to treatment phases around transplant.
What research teams should watch
Coordinate blood-bank testing and stem-cell collection early and keep induction, transplant and consolidation dates distinct.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Newly diagnosed, transplant-eligible myelomaPRIMARY RECORDS